Sorafenib Accord Europska Unija - hrvatski - EMA (European Medicines Agency)

sorafenib accord

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastična sredstva - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Drospifem M 0,02 mg/3 mg filmom obložene tablete Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

drospifem m 0,02 mg/3 mg filmom obložene tablete

mibe pharmaceuticals d.o.o., zavrtnica 17, zagreb, hrvatska - etinilestradiol drospirenon - filmom obložena tableta - 0,02 mg + 3 mg - urbroj: svaka filmom obložena tableta sadrži 0,02 mg etinilestradiola i 3 mg drospirenona